Journal: iScience
Article Title: BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis
doi: 10.1016/j.isci.2025.114526
Figure Lengend Snippet: D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
Article Snippet: BRD2 , Santa Cruz , sc-514103; RRID:AB_3720459.
Techniques: Control, In Vitro, Expressing, Ubiquitin Proteomics, Knockdown, Western Blot, Binding Assay